Who founded XGenomes?

XGenomes was founded by Kalim Mir in 2017.

Who are XGenomes's investors?

XGenomes's investors include FundersClub, Think+ Ventures Management, Llc, Y Combinator, Amino Capital, Cantos Ventures, FCVC, HOF Capital, Romulus Capital and 1 more.

Where is XGenomes headquartered?

XGenomes is headquartered in Boston, US.

XGenomes

YC W19

Boston, US · Founded 2017 · 6 employees · 9 known investors

Find your way into XGenomes

Paths you didn't know you had: your email and LinkedIn already hold routes to the XGenomes team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

XGenomes develops genomic sequencing technology using fluorescent probes and machine learning to read genetic and epigenetic information at single-molecule resolution. The platform enables frequent, rapid, and low-cost screening for healthcare providers and patients to support early disease detection and personalized preventive medicine.

Also known as XGenomes Corp.

AI & Machine Learning Biotech Digital Health Healthtech Medical Devices GenomicsUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (W19)

XGenomes was founded in 2017 by Kalim Mir.

Kalim Mir CEOFounder and CEO of XGenomes. Mir has expertise in genomics, DNA sequencing, single-molecule biochemistry, and microfluidics.

Janey MuñozBio- and Systems Engineer2018–2020

Investors · 9

FundersClublisted by FundersClubSan Francisco · $290K

How we know: funding news · Y Combinator's founder network · Not right? Tell us

Think+ Ventures Management, Llclisted by Think+ Ventures Management, LlcPalo Alto · $200K – $500K

How we know: Think+ Ventures Management, Llc's portfolio page · Y Combinator's founder network · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

Amino CapitalreportedPalo Alto · $100K – $10M

How we know: Y Combinator's founder network · Not right? Tell us

Cantos VenturesreportedSan Francisco · $400K – $1.5M

How we know: a partner's Signal profile · Y Combinator's founder network · Not right? Tell us

FCVCreportedSan Francisco

How we know: funding news · Not right? Tell us

HOF CapitalreportedNew York · $500K – $10M

How we know: funding news · Y Combinator's founder network · Not right? Tell us

Romulus CapitalreportedBoston · $250K – $10M

How we know: Y Combinator's founder network · Not right? Tell us

The Engine VenturesreportedCambridge

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Related companies · 10

One CodexOne Codex provides microbiome sequencing data analysis and reporting software for academic labs, biotechnology companies, and clinical laboratories. The platform uses advanced algorithms and a curated database to analyze metagenomic samples with a web-based interface accessible to both bench scientists and computational biologists.

Luminist LabsLuminist Labs provided a non-invasive test to identify and assess the progression of liver fibrosis and NASH in patients. The company was acquired by DiscernDx in 2020.

10x Genomics10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.

BillionToOneBillionToOne is a precision diagnostics company that uses molecular counting technology to develop non-invasive prenatal screening and liquid biopsy tests for early disease detection. The company focuses on making molecular diagnostics accurate, fast, and accessible to patients.

IDbyDNAScalable, high throughput DNA sequencing platforms.

Helix NanotechnologiesHelix Nanotechnologies develops mRNA-based therapeutics for disease treatment and environmental applications, currently advancing a COVID-19 vaccine candidate for immunocompromised patients and testing interventions targeting climate challenges.

NucleomeNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.

MyomeMyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

nChroma BionChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.

Companies working in the same space as XGenomes.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2018	$280K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2017	$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Legal entities · 1

corporate structure

XGenomes Corp.

Frequently asked questions

What does XGenomes do?: XGenomes develops genomic sequencing technology using fluorescent probes and machine learning to read genetic and epigenetic information at single-molecule resolution. The platform enables frequent, rapid, and low-cost screening for healthcare providers and patients to support early disease detection and personalized preventive medicine.
Who founded XGenomes?: XGenomes was founded by Kalim Mir in 2017.
Who are XGenomes's investors?: XGenomes's investors include FundersClub, Think+ Ventures Management, Llc, Y Combinator, Amino Capital, Cantos Ventures, FCVC, HOF Capital, Romulus Capital and 1 more.
Where is XGenomes headquartered?: XGenomes is headquartered in Boston, US.